Speakers

Hossein Borghaei, Paul Bunn, Jr., Justin Gainor, David Gandara, Ramaswamy Govindan, Fred Hirsch, Mark Kris, Corey Langer, Vassiliki Papadimitrakopoulou, Suresh Ramalingam, Naiyer Rizvi, Lecia Sequist, Mark Socinski, Tom Stinchcombe, Jack West

Hossein Borghaei, DO

Chief, Thoracic Medical Oncology
Director, Lung Cancer Risk Assessment
Fox Chase Cancer Center
Philadelphia, PA

Dr. Borghaei is Chief of Thoracic Medical Oncology and Director of Lung Cancer Risk Assessment at Fox Chase Cancer Center in Philadelphia, PA. He is Board Certified in Medical Oncology, as well as certified by the National Board of Osteopathic Medical Examiners.

Dr. Borghaei received his DO from the Philadelphia College of Osteopathic Medicine and completed his fellowship at Fox Chase Cancer Center and then joined the Center’s Department of Medical Oncology in 2004.
As a medical oncologist, Dr. Borghaei specializes in the diagnosis and treatment of lung cancer—with an additional interest in lung cancer prevention. His practice focuses on offering clinical trials with a concentration on antibodies and other immune-based therapies. Dr. Borghaei’s laboratory research concentrates on the production of monoclonal antibodies against novel targets in tumor blood vessels. These antibodies have the potential for use in the treatment of various cancers, as well as for research on the role that the body’s immune system plays in the fight against cancer. Dr. Borghaei is also an active member of a number of professional societies, including the American Association for Cancer Research, American Society of Clinical Oncology and ECOG’s core thoracic committee.

Back to top

Paul Bunn, Jr., MD, FASCO

Distinguished Professor
James Dudley Endowed Chair of Lung Cancer Research
Division of Medical Oncology
University of Colorado Cancer Center
University of Colorado, School of Medicine
Aurora, CO

Dr. Bunn is Distinguished Professor and the James Dudley Chair in Cancer Research in the Division of Medical Oncology at the University of Colorado Cancer Center of the University of Colorado School of Medicine in Aurora, CO, where he has practiced and taught since 1984.

Dr. Bunn received his BA from Amherst College in Amherst, MA, and received his MD from Weill Cornell Medical College in New York City, NY. He completed an internship and residency at the University of California San Francisco, San Francisco, CA and a fellowship in Medical Oncology at the National Cancer Institute (Bethesda) Program in Bethesda, MD. Dr. Bunn is Board Certified in Internal Medicine and Medical Oncology. He served as the Head of the Division of Medical Oncology from 1984-1992 and as the Director of the University of Colorado Cancer Center from 1986-2009. In the International Association for the Study of Lung Cancer, Dr. Bunn served on the Board of Directors from 1988 to 1994, president from 1997-2000, and CEO from 2004-2014. He was the president of the American Society of Clinical Oncology from 2002-2003.

The author of hundreds of articles, reviews, and book chapters, Dr. Bunn’s research is well known in the cancer world. He focuses primarily on novel therapies for lung cancer. Dr. Bunn has led numerous national and local trials regarding the treatment of lung cancer, and his findings are credited with setting standards in the treatment of the disease.

Dr. Bunn has researched new personalized therapies for lung cancer that cause fewer side effects than traditional, intravenous chemotherapy. He has also studied the genetics of the disease, seeking to learn how gene therapy could be used to combat the disease. Dr. Bunn is currently the Principal Investigator on the Specialized Program in Research Excellence in Lung Cancer (SPORE) grant funded by the National Institutes of Health and the National Cancer Institute that aims to expand understanding about the biology of the disease, as well as to find new methods of diagnosis, prevention, and treatment.

Back to top

Justin Gainor, MD

Instructor in Medicine
Harvard Medical School
Boston, MA

Dr. Gainor is a graduate of Johns Hopkins University in Baltimore, MD and Harvard Medical School in Boston, MA. He completed his Internal Medicine residency at the Massachusetts General Hospital in Boston, MA and his Medical Oncology fellowship in the Dana-Farber Cancer Institute/Partners Cancer Care program. He is currently an Attending Physician in the Center for Thoracic Cancers at the Massachusetts General Hospital Cancer Center and an Instructor in Medicine at Harvard Medical School.

Dr. Gainor has an active clinical and translational research career. His research focuses on the development of novel targeted therapies in genetically-defined subsets of non-small cell lung cancer, with a focus on chromosomal rearrangements (ALK, ROS1, and RET). As part of this work, he is active in studying molecular mechanisms of resistance to targeted therapies, as well as the intersection of targeted therapies and immunotherapies, on both a clinical and translational level.

Back to top

David Gandara, MD

Professor of Medicine
Division of Hematology/Oncology
University of California, Davis School of Medicine
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Dr. Gandara is Professor of Medicine at the University of California at Davis (UC Davis) School of Medicine in Davis, CA, and the Senior Advisor to the Director, and Director of the Thoracic Oncology Program at the UC Davis Comprehensive Cancer Center in Sacramento, CA. He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology. Dr. Gandara is currently Principal Investigator for a number of research projects in lung cancer, pharmacology trials at various phases, and Southwest Oncology Group (SWOG) trials. Dr. Gandara is the Clinical Director for a National Cancer Institute award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents. He is Senior Advisor, Group Chair of SWOG and Chair of the SWOG Lung Committee, 1997-2015. Dr. Gandara is a member and prior co-chair of the NCI-directed Investigational Drug Steering Committee (IDSC).

Dr. Gandara has written over 700 articles, book chapters, abstracts, and editorials. He is Editor-in-chief of the journal, Clinical Lung Cancer, serves on the editorial board of four oncology journals, and is an ad hoc manuscript reviewer for eight additional journals. Dr. Gandara served as president of the International Association for the Study of Lung Cancer (IASLC) from 2009 to 2011 and is on the board of directors of IASLC and was elected as treasurer in 2013. He is a prior board member and secretary-treasurer of the American Society for Clinical Oncology. Dr. Gandara is also Chair of the NCI-directed Lung Correlative Science Committee. After receiving his Medical Degree from the University of Texas Medical Branch in Galveston, TX, Dr. Gandara was an intern and resident at the Madigan Army Medical Center in Tacoma, WA and a Fellow at the Letterman Army Medical Center Presidio of San Francisco, CA.

Back to top

Ramaswamy Govindan, MD

Director of Medical Oncology
Division of Oncology
Professor of Medicine
Department of Medicine
Washington University School of Medicine
St. Louis, MO

Dr. Govindan is the Director of Medical Oncology in the Division of Oncology and Professor of Medicine in the Department of Medicine at Washington University School of Medicine (WUSM) in St. Louis, MO. He received his Medical Degree from the University of Madras in India, and undertook internship and residency training in Internal Medicine at Michael Reese Hospital and Medical Center in Chicago, IL. Dr. Govindan completed his fellowship in Hematology-Oncology at WUSM and joined the faculty in 1998.
Dr. Govindan is interested in studying genomic alterations in lung cancer and translating these findings in the clinic. Dr. Govindan has led several national and international clinical trials in lung cancer. He is the Principal Investigator for the NCI sponsored ALCHEMIST Trial to study the impact of targeted therapy in early stage lung cancer.

Dr. Govindan is the Co-Chair of the lung cancer working group for The Cancer Genome Atlas project funded by the National Cancer Institute (NCI). He is also the Principal Investigator of the NCI sponsored Paul Calabresi K12 Oncology Training Program and the R25 STRENGTH program at WUSM.

Back to top

Fred Hirsch, MD, PhD

Professor of Medicine and Pathology
University of Colorado, School of Medicine
Associate Director
University of Colorado Cancer Center
Denver, CO

Dr. Hirsch is Professor of Medicine and Pathology at the University of Colorado School of Medicine in Denver, CO. His research interests which have spanned more than 25 years include translational research, targeted therapies, and early detection of lung cancer. Dr. Hirsch is also studying biomarkers related to molecular targeted therapies in order to understand the mechanisms of action and resistance of these new therapies, and to be able to select the patients who will benefit from such treatment. The biomarker studies relate to the development of molecular targeted therapies for chemoprevention and treatment of lung cancer including studies on lung cancer cell lines and tumor tissue from clinical cohorts. Within the last year his focus has been on identifying biomarkers, which can be used to select lung cancer patients to EGFR tyrosine kinase inhibitors and other EGFR inhibitors. Dr. Hirsch’s laboratory is currently studying biomarkers in multiple clinical trials performed in the US and Europe both in lung and head and neck cancer.

Dr. Hirsch has served on NCI’s Steering Committee for Thoracic Malignancies Program (CTEP) and is also Co-Chair for Southwest Oncology Group’s (SWOG) Lung Cancer Translational Research Committee. He also serves as Associate Director for the University of Colorado Cancer Center.

In November 2013, Dr. Hirsch became the CEO of the International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer. The IASLC’s membership includes more than 5,000 lung cancer specialists in over 100 countries. He has published more than 300 peer-reviewed scientific articles.

Back to top

Mark Kris, MD, FACP, FACCP

Attending Physician, Thoracic Oncology Service
The William and Joy Ruane Chair in Thoracic Oncology
Lead Physician, Memorial Sloan Kettering–IBM Watson Collaboration
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Dr. Kris is an Attending Physician in the Thoracic Oncology Service at Memorial Hospital, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. He is the first incumbent of the William and Joy Ruane Chair in Thoracic Oncology. Dr. Kris is a Professor of Medicine at the Weill Cornell Medical College in New York, NY. Since 2012, he has served as the Lead Physician for the Memorial Sloan Kettering - IBM Watson Collaboration.

Dr. Kris graduated from Fordham University in Bronx, NY. After receiving his Medical Degree from Weill Cornell Medical College, he served as chief medical resident and fellow in Medical Oncology at Memorial Sloan Kettering Cancer Center.

Dr. Kris is author or coauthor of over 300 original scientific publications. He served as a member of the guideline panels on non-small cell lung cancers and antiemetics for the National Comprehensive Cancer Center Network from 1995-2015. Dr. Kris serves as Co-chair of the guideline panel for adjuvant chemotherapy and radiation for non-small cell lung cancers, and antiemetics for the American Society of Clinical Oncology. He is a Fellow of the American College of Physicians, The American College of Chest Physicians, and The American Society of Clinical Oncology. He received the first American Society of Clinical Oncology Humanitarian Award in 2011. Dr. Kris also received the Annie Blount Storrs Award from Calvary Hospital in 2014.

Dr. Kris is a specialist in lung cancers and other tumors arising in the chest. He is particularly interested in developing ways to choose treatments for patients based on molecular characteristics of their tumor specimens. His research also includes the evaluation of new anticancer agents (particularly those targeting lung cancers), multimodality therapy (using surgery, radiation and drugs together to improve outcomes for individuals with thoracic cancers), and the training of the IBM Watson cognitive computer to assist physicians and patients in choosing the best treatments.

Back to top

Corey Langer, MD, FACP

Professor of Medicine
Hematology/Oncology Division
University of Pennsylvania
Philadelphia, PA

Dr. Langer is Professor of Medicine in the Hematology/Oncology Division at the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA, where he serves as Director of Thoracic Oncology in the Abramson Cancer Center. Dr Langer received his Medical Degree from Boston University in Boston, MA and completed his internship and residency in Medicine at the Graduate Hospital of the University of Pennsylvania in Philadelphia, PA. Additional postgraduate training included a fellowship in Hematology/Oncology at the Penn Presbyterian Medical Center in amd a fellowship in Oncology at AOH/Fox Chase Cancer Center (FCCC), both in Philadelphia, PA. He is Board Certified in Internal Medicine and in Hematology/Oncology.

Dr Langer served in the oncology division of FCCC for 22 years from 1986 until 2008, and for the last 14 years of his tenure at FCCC, he led its Thoracic Oncology Program. He also served as the research chair of Oncology Physicians Network, a consortium of academic and community facilities in the Delaware Valley allied with FCCC. In June of 2008, he moved to the University of Pennsylvania where he currently leads the Interdisciplinary Thoracic Oncology Program (I-TOP).

Dr Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the International Association for the Study of Lung Cancer (IASLC), and the Society of Head and Neck Surgeons. He has served as Vice-Chair of the Radiation Therapy Oncology Group (RTOG, now NRG) and chairs its Medical Oncology Subcommittee. He also serves on the core Thoracic and Head and Neck Committees of both the Eastern Cooperative Oncology Group (ECOG) and RTOG (NRG).

Dr Langer has contributed numerous articles (>200) and abstracts (>250) to the medical literature. His work on head and neck squamous cell cancer and non-small cell lung cancer has appeared in the New England Journal of Medicine, Seminars in Oncology, Clinical Cancer Research, Journal of Clinical Oncology, Journal of Thoracic Oncology, Clinical Lung Cancer, Cancer, Lung Cancer, Cancer Investigation, and EJC. His work has also been presented at the national meetings of ASCO, AACR, ASH, SIOG and the IASLC. He has served three separate terms as a member of the editorial board of the Journal of Clinical Oncology, and is currently on the editorial boards of Clinical Lung Cancer and Clinical Advances in Hematology and Oncology. Dr Langer was also a member of PDQ editorial board/National Cancer Institute protocol submissions and while at FCCC, he served on the NCCN NSCLC and SCLC committees. He reviews articles for the New England Journal of Medicine, Journal of Clinical Oncology, Clinical Lung Cancer, Clinical Cancer Research, Cancer, Annals of Oncology, Lung Cancer, and the Journal of Thoracic Oncology. He is also a frequent lecturer at numerous medical symposia and grand rounds and serves as advisor/commentator for Projects in Knowledge, Impact, CCO, and Medscape.

Back to top

Vassiliki Papadimitrakopoulou, MD

Chief, Section of Thoracic Medical Oncology
Jay and Lori Eisenberg Distinguished Professor of Medicine
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Papadimitrakopoulou is the Jay and Lori Eisenberg Distinguished Professor of Medicine and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas/MD Anderson Cancer Center in Houston, TX. She is nationally recognized for her leadership and expertise in lung cancer treatment and research and best known for her work in personalized therapy of non-small cell lung cancer, in particular the process of linking cancer biomarkers to novel therapies.

Dr. Papadimitrakopoulou is a member of the American Association for Cancer Research, as well as the American Society of Clinical Oncology (ASCO) where she has served as a member of the scientific committee and member of the education committee. She is a member of the Southwest Oncology Group’s lung committee and a member of the membership and publications committees for the International Association for the Study of Lung Cancer. She has authored more than 140 peer-reviewed papers and has in the past received awards from the ASCO (YIA and CDA) and holds current grant funding for her work from numerous sources including the National Cancer Institute (NCI), and multiple charitable foundations.

Dr. Papadimitrakopoulou’s primary interest is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to lung cancer patients. She has conducted translational research studies with particular focus on cell cycle regulation and signal transduction in both premalignant lesions and established cancer. Dr. Papadimitrakopoulou has been the principal investigator on over 50 phase I and II clinical trials with novel targeted agents including cell cycle inhibitors, farnesyl transferase inhibitors, pro-drugs, tyrosine kinase inhibitors, immunotherapy, and chemoprevention studies. She led the BATTLE-2 trial a biomarker-driven multi-investigator clinical trial and is currently the national leader of the Lung MAP trial, a unique private-public partnership, using a diagnostic next-generation sequencing assay as a screening tool for an umbrella project aiming at approval of targeted therapies and immunotherapies in the context of refractory to standard therapy squamous lung cancer and sponsored by the NCI, National Clinical Trials Network.

Dr. Papadimitrakopoulou is a member of the Editorial Boards of Annals of Oncology, Journal of Clinical Oncology, Investigational New Drugs, Anticancer Research, Clinical Cancer Prevention, Cancer, and Clinical Cancer Research. She received her Medical Degree from The University of Patras Medical School in Greece and completed her Internal Medicine residency at Columbia Presbyterian Medical Center, New York, NY and her Medical Oncology fellowship at the University of Texas/MD Anderson Cancer Center in Houston, TX, and has completed a Graduate Certificate in Health Care Management at Rice University in Houston, TX.

Back to top

Suresh Ramalingam, MD

Professor of Hematology and Medical Oncology
Director, Division of Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Atlanta, GA

Dr. Ramalingam is Professor of Hematology and Medical Oncology and the Assistant Dean for Cancer Research at the Emory University School of Medicine in Altanta, GA. He is also the Deputy Director of the Winship Cancer Institute of Emory University.

Dr. Ramalingam received his Medical Degree at Kilpauk Medical College in Madras, India. He completed his residency in Internal Medicine at Wayne State University in Detroit, MI, where he also served as Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center in Pittsburgh, PA.

Dr. Ramalingam serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee. He also serves on the Editorial Board of leading cancer journals such as the Journal of Clinical Oncology, Annals of Oncology, Cancer, Clinical Lung Cancer, and Translational Lung Cancer Research. Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence in Teaching from the Department of Hematology and Medical Oncology, Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award, and the NCI Clinical Investigators Team Leadership Award (2010-12). Dr. Ramalingam serves on several international, national, and institutional committees.

Dr. Ramalingam’s research interests include development of novel anti-cancer agents and evaluation of methods to individualize therapies for patients. He has conducted several clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer. Dr. Ramalingam has published more than 200 original manuscripts, review articles, editorials and book chapters.

Back to top

Naiyer Rizvi, MD

Professor of Medicine
Director, Thoracic Oncology and Immunotherapeutics
Division of Hematology and Oncology
Columbia University Medical Center
New York, NY

Dr. Rizvi is the Professor of Medicine in the Department of Medicine and the Director of Thoracic Oncology Phase I Immunotherapeutics for the Division of Hematology and Oncology at Columbia University Medical Center in New York, NY. He also holds the Price Chair in Clinical Translational Research.

Dr. Rizvi is an internationally recognized leader in the treatment of lung cancer and immunotherapy drug development. Prior to joining Columbia University Medical Center, his clinical research at Memorial Sloan Kettering Cancer played a significant role in the FDA approval path of a new class of immunotherapies, called immune checkpoint inhibitors, for melanoma and lung cancer.

Dr. Rizvi’s research focus is studying mechanisms of sensitivity and resistance to immunotherapy. Through genetic testing of tumors, he has been able to improve the understanding of why immune checkpoint inhibitors work in certain patients. This work has been partially supported by Stand Up to Cancer – Cancer Research Institute Immunology funding.

In his research, he also is studying why certain cancers do not respond to immune checkpoint inhibitors, so we can find better ways to harness the immune system to attack cancer cells. He oversees phase 1 immunotherapy research in solid tumors at Columbia University Medical Center and is conducting key clinical studies of novel immunotherapy drugs and immunotherapy combinations to help more patients in the fight against cancer.

Dr. Rizvi has disclosed that he is a consultant for AstraZeneca, Merck, Novartis, and Roche. He is also a shareholder/co-founder of Gritstone Oncology.

Back to top

Lecia Sequist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, MA

Dr. Sequist is originally from Michigan and studied chemistry at Cornell University in Ithaca, NY. She received her MD from Harvard Medical School in Boston, MA and trained in Internal Medicine at the Brigham and Women’s Hospital and in Hematology/Oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health.

Dr. Sequist joined the faculty of the Center for Thoracic Cancers at the Massachusetts General Hospital Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently an Associate Professor of Medicine at Harvard Medical School and the Mary B. Saltonstall Endowed Chair in Medical Oncology at Massachusetts General Hospital. Dr. Sequist has held grants from the National Institutes of Health (NIH), the Department of Defense (DOD), and many private foundations. Her research focuses on studying novel targets for lung cancer treatment, especially in patients with EGFR mutations and other driver oncogenes. Dr. Sequist also studies the changes that occur in cancers at the time of acquired drug resistance through tumor biopsies and non-invasive tests like CTC’s and ctDNA. She aims to develop personalized treatment algorithms for lung cancer, utilizing targeted therapies specific to the patients’ cancer genotypes, and understanding how this may change over the courses of the disease.

Back to top

Mark Socinski, MD

Executive Medical Director
Florida Hospital Cancer Institute
Orlando, FL

Dr. Socinski is the Executive Medical Director of the Florida Hospital Cancer Institute in Orlando, FL. He received his Medical Degree from the University of Vermont, College of Medicine in Burlington, VT. His postdoctoral training included an internship and residency in Internal Medicine at the Beth Israel Hospital, Harvard Medical School and a Medical Oncology fellowship at the Dana-Farber Cancer Institute, Harvard Medical School both in Boston, MA. Dr. Socinski was most recently the Director of the Lung Cancer Section at the University of Pittsburgh Medical Center (UPMC), Clinical Associate Director of the University of Pittsburgh Lung Cancer SPORE, Co-Director of UPMC Lung Cancer Center of Excellence, and Co-Leader of the Lung Cancer Program at the University of Pittsburgh Cancer Institute in Pittsburgh, PA.

Dr. Socinski holds membership in numerous professional societies such as the American College of Physicians, American Society of Clinical Oncology, Cancer and Leukemia Group B, International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He is also Co-Chair Emeritus of the Thoracic Malignancies Steering Committee for the National Cancer Institute.

Dr. Socinski is well-published in peer-reviewed literature in outstanding journals such as the Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer, and Lancet Oncology. His primary research interests reside in all aspects of clinical trials related to the thoracic oncology population. He also has been instrumental in the development of many cooperative group and investigator-initiated clinical trials.

Back to top

Tom Stinchcombe, MD

Division of Medical Oncology
Duke University Medical Center
Durham, NC

Dr. Stinchcombe completed medical school at the University of Virginia in Charlottesville, VA, his Internal Medicine residency at the University of Michigan in Ann Arbor, MI, and his Hematology and Oncology fellowship at the University of North Carolina in Chapel Hill, NC. His clinical interest is in thoracic malignancies, and his research focus is clinical trials for non-small-cell and small-cell lung cancer. He is a member of the Duke Cancer Institute and the thoracic oncology program. He is a member of the Respiratory Committee of the Alliance Cooperative trials group and Board Member for Academic and Community Cancer Research United. He is an associate editor of the Journal of Thoracic Oncology.

Back to top

Jack West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Web Editor, JAMA Oncology
Founder & President
GRACE: Global Resource for Advancing Cancer Education
Seattle, WA

Dr. West received an MPhil in Experimental Biology from Cambridge University in Cambridge, United Kingdom on a Fulbright Scholarship and a Medical Degree (magna cum laude) from Harvard Medical School in Boston, MA, where he also conducted research as a Howard Hughes Medical Student Fellow. Dr. West’s postdoctoral training included an internship and residency in Internal Medicine at the Harvard-affiliated Brigham and Women’s Hospital, followed by a fellowship in Medical Oncology at the Fred Hutchinson Cancer Research Center/University of Washington in Seattle, WA.

Dr. West joined Swedish Cancer Institute in late 2002 as a medical oncologist and lung cancer specialist. He also serves as Medical Director of the Thoracic Oncology Program and has a significant clinical interest as well in genitourinary oncology.

Dr. West has published numerous articles in peer-reviewed literature and has authored several book chapters. He also now serves as the Web Editor of JAMA Oncology and is on the editorial boards of Journal of Clinical Oncology, Journal of Medicine, Clinical Lung Cancer, and Journal of Thoracic Disease, in addition to serving as an author of multiple lung cancer-related sections of UpToDate® and as a reviewer for more than a dozen professional journals. Dr. West leads a wide range of clinical trials and has been actively involved with the SWOG Lung Cancer Committee as a study coordinator/principal investigator.

Dr. West founded and continues to serve as President of the nonprofit organization, Global Resource for Advancing Cancer Education (GRACE), a source of timely, free information for patients and caregivers dealing with cancer that currently receives over 50 thousand visits per month from over 100 countries around the world. He is also working to develop telemedicine-based practice patterns to broaden the range of treatment options for cancer patients and serves as the Chair of the Outreach/Education/Telemedicine Working Group for the Cancer Clinical Provider Group as part of the Providence/Swedish Hospital Network.

Back to top